Axsome Therapeutics, Inc
AXSM
144.37−4.87 (−3.26%)Nov 12, 4:58 PM ET
Key stats
- Open
- 148.07
- Day high
- 150.34
- Day low
- 144.01
- Previous close
- 149.24
- Volume
- 979.6K
- VWAP
- 146.23
- 52-week high
- 260.19
- 52-week low
- 123.00
- Market cap
- 7.85B
- Shares out
- 52.60M
- Employees
- 925
- Listed
- 2015
About Axsome Therapeutics, Inc
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
PHARMACEUTICAL PREPARATIONS · NEW YORK, NY · axsome.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 2.4K
- Put open interest
- 879
- Put/call
- 0.37
- At-the-money IV
- 59.7%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 165 call | 0.50 | Nov 12, 1:36 PM | 451 | 1.2K | 61.1% |
| 145 call | 4.75 | Nov 12, 2:48 PM | 55 | 98 | 59.7% |
| 120 call | 23.20 | Nov 3, 10:03 AM | 40 | 28 | — |
| 150 call | 3.27 | Nov 12, 3:25 PM | 25 | 216 | 54.1% |
| 140 call | 11.46 | Nov 12, 11:29 AM | 17 | 137 | 46.2% |
| 170 put | 37.47 | Nov 6, 12:51 PM | 14 | 61 | 96.5% |
Quarterly results
Massive · Nov 2, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $259.69M | $218.38M | $191.20M | $196.00M |
| Gross profit | $241.89M | $204.81M | $176.48M | $183.67M |
| Operating income | −$11.07M | −$49.65M | −$63.36M | −$26.96M |
| Net income | −$12.88M | −$51.31M | −$64.54M | −$28.56M |
| Diluted EPS | -0.25 | -0.99 | -1.26 | -0.56 |
| Operating cash flow | −$9.47M | −$32.95M | −$20.70M | −$18.65M |
| Assets | $826.77M | $761.45M | $713.61M | $689.80M |
| Liabilities | $721.34M | $678.14M | $659.02M | $601.51M |
| Equity | $105.43M | $83.30M | $54.59M | $88.30M |
Technicals
Massive · Nov 12, 2026- 50-day average172.78
- 200-day average197.26
- RSI (14 days)42.8
Short interest
Massive · Oct 30, 2026- Oct 30, 20263.26M shares · 3.4 days to cover
- Oct 15, 20263.11M shares · 3.3 days to cover
- Sep 30, 20263.31M shares · 4.4 days to cover
- Sep 15, 20263.14M shares · 5.2 days to cover
Related companies
MassiveNews coverage
No stories about Axsome Therapeutics, Inc right now.